Acurx Pharmaceuticals, Inc.’s (NASDAQ: ACXP) ($ACXP) interview with David Luci, President/CEO.

Click the Subscribe button for the latest in crypto, blockchain and business news from NEW TO THE STREET!

#crypto #cryptocurrency #blockquake #blockchain #blockchainnews #digitalcurrency #newtothestreet #janeking #exploringtheblock #foxbusinessnews #foxbusiness #financialnews #businessnews #ai #newsmaxtv

David Luci, the President/CEO at Acurx Phamaceuticals, Inc. (NASDAQ: ACXP) ($ACXP), is at the Nasdaq Marketsite studio, talking with New to The Street’s TV Host Jane King about the Company. Acurx Phamaceuticals, Inc. is a clinical-stage biopharmaceutical business developing a new class of antibiotics for life-threatening bacterial infections. David provides viewers an update on the Company’s FDA Phase 2b trial on its Ibezapolstat drug for treating Clostridioides difficile Infections (CDI) (C. diff). Thirty-six patients are enrolled in the trial, and Management expects that patient enrollment will end in December 2023. The current FDA trial is one of three value propositions the Company pursues throughout the second half of 2023. With bi-partisan support, the US Congress looks to pass the PASTEUR Act of 2023, designed to allow federal funds to flow to companies like Acurx developing a new class of antibiotic treatments for highly infectious diseases. The $370.5M congressional earmark will help create new antibiotics to save lives and reduce healthcare costs by approximately $2B over the next ten years. Medicaid, Medicare, and VA patients will receive these new antibiotics at no cost. Current treatments for Clostridioides difficile Infections (CDI) (C. diff) and MRSA (methicillin-resistant Staphylococcus aureus) have become resistant, no longer providing protective solutions to those infected. The US CDC (Center for Disease Control and Prevention) and WHO (World Health Organization) reported that a new class of antibiotics must combat diseases resistant to the old drugs currently in use. David gives a glimpse at the 5-year plan at the Company, with the expectation that its Ibezpolstat drug is generating millions of dollars for the treatment of C. diff. And the Company is looking to roll out a second pipeline novel drug for treating MRSA and the skin problems associated with those infected with MRSA. The on-screen QR code is available during the show; download or visit Acurx Pharmaceticals, Inc. – https://www.acurxpharma.com/. The interview will air on Newsmax, episode 486, July 8, 2023, 3:30 PM ET, and on the FOX Business Network, episode 487, July 10, 10:30 PM PT.

To make sure you never miss a video from New to the Street, click here to subscribe: https://www.youtube.com/c/newtothestreettv

Follow New to the Street on Twitter: https://twitter.com/NewToTheStreet

Follow New to the Street on Facebook: https://www.facebook.com/newtothestreet/

Follow New to the Street on Instagram: https://www.instagram.com/newtothestreettv/

Follow New to the Street on Rumble: https://rumble.com/user/newtothestreet

About New to the Street: https://newtothestreet.com/

Subscribe to our Mailing List: https://mailchi.mp/ccd21b3e3fab/join-our-mailing-list